JMP Securities Maintains Evolent Health(EVH.US) With Buy Rating, Raises Target Price to $43
Evolent Health Buy Rating Affirmed With Increased Price Target Amid Growth Prospects and M&A Speculation
Evolent Health Is Maintained at Buy by Truist Securities
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating
Evolent Health Price Target Maintained With a $42.00/Share by RBC Capital
Evolent Health Analyst Ratings
RBC Capital Reiterates Outperform on Evolent Health, Maintains $42 Price Target
Truist Financial Sticks to Its Buy Rating for Evolent Health (EVH)
RBC Capital Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $42
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating
Evolent Health (EVH) Gets a Buy From RBC Capital
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Evolent Health (EVH)
A Quick Look at Today's Ratings for Evolent Health(EVH.US), With a Forecast Between $38 to $45
Evolent Health Analyst Ratings
JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $45
J.P. Morgan Maintains Evolent Health(EVH.US) With Buy Rating, Announces Target Price $45
CCORF Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $33
Evolent Health Poised for Growth: Strategic Acquisition and Strong Organic Prospects Fuel Buy Rating
RBC Capital Keeps Their Buy Rating on Evolent Health (EVH)
Evolent Health (EVH): A Buy Rating With Robust Growth and Strategic Initiatives
No Data
No Data